Email this article 
Association of Prior COVID‑19 Infection with Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran
Abstract
Background: Many people worldwide have developed a combination of natural and vaccine‑induced immunity to COVID‑19. This study investigated whether exposure to SARS‑CoV‑2 before full vaccination promotes protection against a breakthrough infection. Methods: We studied a total of 2,902,545 people in the Isfahan COVID‑19 Registry. All the participants had received two doses of either Sinopharm BIBP, ChAdOx1‑nCoV‑19, Gam‑COVID‑Vac, or BIV1‑CovIran vaccines. A cohort study examined the association between prior COVID‑19 infection and the risk of a breakthrough infection for each vaccine. Cohorts in each pair were matched by gender, age group, calendar week of the first dose, the interval between the first and second doses, and the proportion of healthcare workers. The probable virus variant for the previous infections was also considered. Each individual’s follow‑up started 14 days after their second vaccine dose until either the end of the study censoring date, occurrence of a COVID‑19 infection, or death. The breakthrough infection risk was compared between each cohort pair by using the hazard ratio (HR) and incidence rate ratio (IRR). Results: Total breakthrough HRs (95% confidence interval) (previously infected over infection‑naïve matched cohort) were 0.36 (0.23–0.55), 0.35 (0.32–0.40), 0.37 (0.30–0.46), and 0.43 (0.32–0.56) for the BIV1‑CovIran, Sinopharm BIBP, Gam‑COVID‑Vac, and ChAdOx1‑nCoV‑19 vaccine groups, respectively. The breakthrough infection IRRs were approximately similar to the total HRs mentioned above. Conclusion: Prior SARS‑CoV‑2 infection conferred additive immunity against breakthrough after vaccination, no matter which vaccine brand was injected. Such a result could guide health authorities to codify low‑cost high‑benefit vaccination protocols and protect the community’s well‑being.
International Journal of Preventive Medicine 15():18, April 2024. | DOI: 10.4103/ijpvm.ijpvm_173_23
Corresponding Authors:
Dr. Maryam Nasirian
E‑mail: maryamnasirian17@gmail.com
You can also search for this author in: PubMed Google Scholar
Dr. Shaghayegh Haghjooy Javanmard
E‑mail: shaghayegh.haghjoo@gmail.com
You can also search for this author in: PubMed Google Scholar
Keywords
Full Text:
PDFReferences
COVID‑19 by County: Centers for Disease Control and
Prevention; 2022 [updated Mar 24, 2022]. Available from:
https://www.cdc.gov/coronavirus/2019‑ncov/your‑health/covid‑
by‑county.html.
COVID‑19: Center for Disease Control and Prevention; 2024
Available from: https://wwwnc.cdc.gov/travel/diseases/covid19.
[Last accessed on 2024 Mar 04].
WHO Coronavirus (COVID‑19) Dashboard: World Health
Organization; 2022 [updated June 10, 2022]. Available from:
https://covid19.who.int.
How to Protect Yourself and Others: Center for Disease Control
and Prevention; 2023 Available from: https://www.cdc.gov/
coronavirus/2019‑ncov/prevent‑getting‑sick/prevention.html.
[Last accessed on 2023 Jul 06].
Coping with Stress: Centers for Disease Control and Prevention;
[updated March 25, 2022]. Available from: https://www.
cdc.gov/mentalhealth/stress‑coping/cope‑with‑stress/index.html.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al.
Research and development on therapeutic agents and vaccines
for COVID‑19 and related human coronavirus diseases. ACS
Central Science 2020;6:315‑31.
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF.
Progress of the COVID‑19 vaccine effort: Viruses, vaccines
and variants versus efficacy, effectiveness and escape. Nat Rev
Immunol 2021;21:626‑36.
McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S,
MacDonald N, et al. COVID‑19 vaccine strategies must focus on
severe disease and global equity. Lancet 2022;399:406‑10.
Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S,
Klesh R, et al. Association of SARS‑CoV‑2 seropositive
antibody test with risk of future infection. JAMA Intern Med
;181:672‑9.
Lumley SF, O’Donnell D, Stoesser NE, Matthews PC,
Howarth A, Hatch SB, et al. Antibody status and incidence of
SARS‑CoV‑2 infection in health care workers. N Engl J Med
;384:533‑40.
Danza P, Koo TH, Haddix M, Fisher R, Traub E, K OY, et al.
SARS‑CoV‑2 infection and hospitalization among adults aged
≥18 years, by vaccination status, before and during SARS‑CoV‑2
B.1.1.529 (Omicron) variant predominance‑Los Angeles County,
California, November 7, 2021‑January 8, 2022. MMWR Morb
Mortal Wkly Rep 2022;71:177‑81.
Goldberg Y, Mandel M, Bar‑On YM, Bodenheimer O,
Freedman LS, Ash N, et al. Protection and Waning of Natural
and Hybrid Immunity to SARS‑CoV‑2. New England Journal of
Medicine 2022;386:2201‑12.
Abu‑Raddad LJ, Chemaitelly H, Ayoub HH, Tang P, Coyle P,
Hasan MR, et al. Relative infectiousness of SARS‑CoV‑2
vaccine breakthrough infections, reinfections, and primary
infections. Nat Commun 2022;13:532.
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D,
Lorenzi JC, et al. Escape from neutralizing antibodies by
SARS‑CoV‑2 spike protein variants. Elife 2020;9:e61312.
Pilz S, Theiler‑Schwetz V, Trummer C, Krause R, Ioannidis JPA.
SARS‑CoV‑2 reinfections: Overview of efficacy and duration of
natural and hybrid immunity. Environ Res 2022;209:112911.
Shenai MB, Rahme R, Noorchashm H. Equivalency of protection
from natural immunity in COVID‑19 recovered versus fully
vaccinated persons: A systematic review and pooled analysis.
Cureus 2021;13:e19102.
Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O,
Vihta K‑D, et al. Impact of vaccination on new SARS‑CoV‑2
infections in the United Kingdom. Nat Med 2021;27:1370‑8.
Stay Up to Date with COVID‑19 Vaccines: Center for Disease
Control and Prevention; 2024. Available from: https://www.cdc.
gov/coronavirus/2019‑ncov/vaccines/stay‑up‑to‑date.html. [Last
accessed on 2024 Mar 07].
Abu‑Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM,
Benslimane FM, Al Khatib HA, et al. Association of prior
SARS‑CoV‑2 infection with risk of breakthrough infection
following mRNA vaccination in Qatar. JAMA 2021;326:1930‑9.
Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R,
Chattopadhyay S, Das B, et al. Sub‑optimal neutralisation of
omicron (B.1.1.529) variant by antibodies induced by vaccine
alone or SARS‑CoV‑2 Infection plus vaccine (hybrid immunity)
post 6‑months. EBioMedicine 2022;78:103938.
Javanmard SH, Nasirian M, Ataei B, Vaseghi G, Vaezi A,
Changiz T. Isfahan COvid‑19 REgistry (I‑CORE): Design and
methodology. J Res Med Sci 2020;25:32.
Sheikhi F, Yousefian N, Tehranipoor P, Kowsari Z. Estimation
of the basic reproduction number of Alpha and Delta variants of
COVID‑19 pandemic in Iran. PLoS One 2022;17:e0265489.
Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S,
et al. Antibody response to the BNT162b2 mRNA COVID‑19
vaccine in subjects with prior SARS‑CoV‑2 infection. Viruses
;13:422.
Ebinger JE, Fert‑Bober J, Printsev I, Wu M, Sun N, Prostko JC,
et al. Antibody responses to the BNT162b2 mRNA vaccine in
individuals previously infected with SARS‑CoV‑2. Nat Med
;27:981‑4.
Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A,
et al. Quantitative SARS‑CoV‑2 anti‑spike responses to
Pfizer‑BioNTech and Oxford‑AstraZeneca vaccines by previous
infection status. Clin Microbiol Infect 2021;27:1516.e7‑14.
Ontañón J, Blas J, de Cabo C, Santos C, Ruiz‑Escribano E,
García A, et al. Influence of past infection with SARS‑CoV‑2
on the response to the BNT162b2 mRNA vaccine in health
care workers: Kinetics and durability of the humoral immune
response. EBioMedicine 2021;73:103656.
Bates Timothy A, McBride Savannah K, Leier Hans C,
Guzman G, Lyski Zoe L, Schoen D, et al. Vaccination before
or after SARS‑CoV‑2 infection leads to robust humoral response
and antibodies that effectively neutralize variants. Sci Immunol
;7:eabn8014. doi: 10.1126/sciimmunol.abn8014.
Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K.
Reduced risk of reinfection with SARS‑CoV‑2 after COVID‑19
vaccination‑Kentucky, May‑June 2021. MMWR Morb Mortal
Wkly Rep 2021;70:1081‑3.
Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C,
et al. Covid‑19 breakthrough infections in vaccinated health care
workers. N Engl J Med 2021;385:1474‑84.
Andreano E, Paciello I, Piccini G, Manganaro N, Pileri P,
Hyseni I, et al. Hybrid immunity improves B cells and antibodies
against SARS‑CoV‑2 variants. Nature 2021;600:530‑5.
Jung MK, Jeong SD, Noh JY, Kim DU, Jung S, Song JY, et al.
BNT162b2‑induced memory T cells respond to the Omicron
variant with preserved polyfunctionality. Nat Microbiol
;7:909‑17.
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S,
et al. Waning immune humoral response to BNT162b2 Covid‑19
vaccine over 6 months. N Engl J Med 2021;385:e84.
Goldberg Y, Mandel M, Bar‑On YM, Bodenheimer O,
Freedman L, Haas EJ, et al. Waning immunity after the
BNT162b2 vaccine in Israel. N Engl J Med 2021;385:e85.
Feikin DR, Higdon MM, Abu‑Raddad LJ, Andrews N, Araos R,
Goldberg Y, et al. Duration of effectiveness of vaccines against
SARS‑CoV‑2 infection and COVID‑19 disease: Results of a
systematic review and meta‑regression. Lancet 2022;399:924‑44.
Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z,
Kanannejad Z, Yaghobi R, et al. An update on protective
effectiveness of immune responses after recovery from
COVID‑19. Front Immunol 2022;13:884879.
Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA,
Franko N, et al. Imprinted SARS‑CoV‑2‑specific memory
lymphocytes define hybrid immunity. Cell 2022;185:1588‑601.e14.
Li C, Yu D, Wu X, Liang H, Zhou Z, Xie Y, et al. Twelve‑month
specific IgG response to SARS‑CoV‑2 receptor‑binding domain
among COVID‑19 convalescent plasma donors in Wuhan. Nat
Commun 2021;12:1‑9.
Powell AA, Kirsebom F, Stowe J, Ramsay ME, Lopez‑Bernal J,
Andrews N, et al. Protection against symptomatic infection
with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2
SARS‑CoV‑2 variants after previous infection and vaccination in
adolescents in England, August, 2021‑March, 2022: A national,
observational, test‑negative, case‑control study. Lancet Infect Dis
;23:435‑44.